Skip to search formSkip to main contentSkip to account menu

Stroke: Working Toward a Prioritized World Agenda

The Synergium was to devise and prioritize new ways of accelerating progress in reducing the risks, effects, and consequences of stroke by using a “Brain Health” concept that enables promotion of preventive measures.
View on Wolters Kluwer (opens in a new tab)

Predictors and Biomarkers of Treatment Gains in a Clinical Stroke Trial Targeting the Lower Extremity

A multimodal model incorporating behavioral and fMRI measures best predicted treatment-induced changes in gait velocity in a clinical trial setting, and results suggest potential use of f MRI measures as biomarkers of treatment gains.
View on Wolters Kluwer (opens in a new tab)

Randomized, Placebo-Controlled, Double-Blind Study of Ropinirole in Chronic Stroke

Ropinirole+PT was generally safe and well tolerated, including no drug-related serious adverse events, and significant gains were found over time for gait velocity and for most secondary end points, however, gains did not differ by treatment assignment.
View on Wolters Kluwer (opens in a new tab)

Stroke: Working toward a Prioritized World Agenda

The aim of the Synergium was to devise and prioritize new ways of accelerating progress in reducing the risks, effects, and consequences of stroke by using a ***‘Brain Health’ concept that enables promotion of preventive measures.
View on SAGE (opens in a new tab)

Proof-of-Concept Randomized Trial of the Monoclonal Antibody GSK249320 Versus Placebo in Stroke Patients

GSK249320, within 72 hours of stroke, demonstrated no improvement on gait velocity compared with placebo, findings potentially useful to future studies aiming to use a monoclonal antibody to modify activity in specific biological pathways to improve recovery from stroke.
View on Wolters Kluwer (opens in a new tab)

Stroke: Working toward a Prioritized World Agenda

The Synergium was to devise and prioritize new ways of accelerating progress in reducing the risks, effects, and consequences of stroke by using a ‘Brain Health’ concept that enables promotion of preventive measures.
View on PubMed (opens in a new tab)

Safety, Pharmacokinetics, and Pharmacodynamics of Escalating Repeat Doses of GSK249320 in Patients With Stroke

Modality-specific end points could be consistently measured in the first few days after stroke, and one of these, gait velocity, demonstrated a trend toward improvement with GSK249320 compared with placebo, suggesting that this first study of a monoclonal antibody to modulate the neurobiology of brain repair after stroke was generally well tolerated.
View on Wolters Kluwer (opens in a new tab)

Methods for an International Randomized Clinical Trial to Investigate the Effect of Gsk249320 on Motor Cortex Neurophysiology using Transcranial Magnetic Stimulation in Survivors of Stroke

Standardized methods of applying TMS motor cortex assessments in an international clinical trial of a pharmacological intervention for stroke patients, which was conducted at 15 centers in three countries, are described.
View PDF (opens in a new tab)

Safety , Pharmacokinetics , and Pharmacodynamics of Escalating Repeat Doses of GSK 249320 in Patients With Stroke

GSK249320 is a humanized monoclonal antibody that binds with high specificity to MAG and antagonizes or neutralizes MAG-mediated inhibition and has been shown to improve functional recovery after stroke in pre-clinical models, possibly by promoting neuroregeneration and plasticity.

Ropinirole in the treatment of motor deficits after stroke: A randomized, placebo-controlled, double-blind study

This research presents a “robust case study” of the immune system’s response to the presence of infectious disease in eight people over a 12-month period.
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)